By Helena Smolak
Roche Holding said it will initiate a late-stage trial for its Alzheimer's drug candidate trontinemab later this year after its mid-stage study showed positive results.
The Swiss pharma giant said Thursday during a conference that its experimental treatment showed a reduction of amyloid plaques--protein clumps in the brain that contribute to the disease's progression--in patients with Alzheimer's disease.
In addition, its plasma diagnostics test Elecsys pTau181 demonstrated the ability to determine whether or not someone has amyloid pathology, one of the hallmarks of Alzheimer's disease.
"We are pleased with the progress across our Alzheimer's portfolio as we move ahead with a Phase III trontinemab program and continue to expand our diagnostic solutions," Levi Garraway, Roche's Chief Medical Officer said.
More than 55 million people worldwide are living with dementia, of which around 70% have Alzheimer's. Up to three-quarters of people experiencing symptoms of Alzheimer's remain undiagnosed, according to Roche.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
April 03, 2025 09:30 ET (13:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.